Infezione da polyomavirus BK e patologia correlata dopo trapianto renale

Translated title of the contribution: Polyomavirus BK-associated nephropathy after kidney transplant

Fabrizio Ginevri, Michela Cioni, Angelica Parodi, Niki Zavras, Patrizia Comoli

Research output: Contribution to journalArticle

Abstract

Advances in immunosuppression have lowered the acute rejection rates in kidney transplant recipients but have impacted negatively on the viral infection rates. Polyomavirus-associated interstitial nephropathy (PyVA N) affects up to 10% of kidney transplant recipients and can progress to irreversible allograft failure in up to 45% of affected cases. Nowadays, thanks to increased awareness of PyVA N and improved diagnostic techniques, the rate of graft loss has decreased, most markedly in centers with active screening and intervention programs. The diagnosis of PyVA N is made by allograft histology. However, systematic screening by quantitative molecular-genetic techniques allows intervention in the early stages of the disease, before the occurrence of irreversible parenchymal changes. So far, the only proven measure affecting PyVA N progression and outcome is the reduction of immunosuppression. Other therapeutic approaches including cidofovir, leflunomide, fluoroquinolones and intravenous immunoglobulins have been explored, but there is no clinical evidence supporting their efficacy. It has been largely demonstrated that BKV-specific T-cell immunity plays a pivotal role in controlling viral replication and disease progression. For this reason viral-specific T-cell immunity can help in monitoring PyVA N. Protocols of adoptive T-cell transfer based on infusion of BKV-specific T cells are the object of many studies and should be considered an innovative treatment approach for PyVA N.

Original languageItalian
Pages (from-to)S99-S108
JournalGiornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
Volume29
Publication statusPublished - Sep 1 2012

Fingerprint

BK Virus
Polyomavirus
T-Lymphocytes
Transplants
Kidney
leflunomide
Virus Diseases
Immunosuppression
Allografts
Immunity
Genetic Techniques
Adoptive Transfer
Intravenous Immunoglobulins
Fluoroquinolones
Disease Progression
Molecular Biology
Histology
Therapeutics
Transplant Recipients

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Infezione da polyomavirus BK e patologia correlata dopo trapianto renale. / Ginevri, Fabrizio; Cioni, Michela; Parodi, Angelica; Zavras, Niki; Comoli, Patrizia.

In: Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia, Vol. 29, 01.09.2012, p. S99-S108.

Research output: Contribution to journalArticle

@article{885563517cbb4549818c8df32f9aa450,
title = "Infezione da polyomavirus BK e patologia correlata dopo trapianto renale",
abstract = "Advances in immunosuppression have lowered the acute rejection rates in kidney transplant recipients but have impacted negatively on the viral infection rates. Polyomavirus-associated interstitial nephropathy (PyVA N) affects up to 10{\%} of kidney transplant recipients and can progress to irreversible allograft failure in up to 45{\%} of affected cases. Nowadays, thanks to increased awareness of PyVA N and improved diagnostic techniques, the rate of graft loss has decreased, most markedly in centers with active screening and intervention programs. The diagnosis of PyVA N is made by allograft histology. However, systematic screening by quantitative molecular-genetic techniques allows intervention in the early stages of the disease, before the occurrence of irreversible parenchymal changes. So far, the only proven measure affecting PyVA N progression and outcome is the reduction of immunosuppression. Other therapeutic approaches including cidofovir, leflunomide, fluoroquinolones and intravenous immunoglobulins have been explored, but there is no clinical evidence supporting their efficacy. It has been largely demonstrated that BKV-specific T-cell immunity plays a pivotal role in controlling viral replication and disease progression. For this reason viral-specific T-cell immunity can help in monitoring PyVA N. Protocols of adoptive T-cell transfer based on infusion of BKV-specific T cells are the object of many studies and should be considered an innovative treatment approach for PyVA N.",
author = "Fabrizio Ginevri and Michela Cioni and Angelica Parodi and Niki Zavras and Patrizia Comoli",
year = "2012",
month = "9",
day = "1",
language = "Italian",
volume = "29",
pages = "S99--S108",
journal = "Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia",
issn = "0393-5590",
publisher = "Wichtig Publishing Srl",

}

TY - JOUR

T1 - Infezione da polyomavirus BK e patologia correlata dopo trapianto renale

AU - Ginevri, Fabrizio

AU - Cioni, Michela

AU - Parodi, Angelica

AU - Zavras, Niki

AU - Comoli, Patrizia

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Advances in immunosuppression have lowered the acute rejection rates in kidney transplant recipients but have impacted negatively on the viral infection rates. Polyomavirus-associated interstitial nephropathy (PyVA N) affects up to 10% of kidney transplant recipients and can progress to irreversible allograft failure in up to 45% of affected cases. Nowadays, thanks to increased awareness of PyVA N and improved diagnostic techniques, the rate of graft loss has decreased, most markedly in centers with active screening and intervention programs. The diagnosis of PyVA N is made by allograft histology. However, systematic screening by quantitative molecular-genetic techniques allows intervention in the early stages of the disease, before the occurrence of irreversible parenchymal changes. So far, the only proven measure affecting PyVA N progression and outcome is the reduction of immunosuppression. Other therapeutic approaches including cidofovir, leflunomide, fluoroquinolones and intravenous immunoglobulins have been explored, but there is no clinical evidence supporting their efficacy. It has been largely demonstrated that BKV-specific T-cell immunity plays a pivotal role in controlling viral replication and disease progression. For this reason viral-specific T-cell immunity can help in monitoring PyVA N. Protocols of adoptive T-cell transfer based on infusion of BKV-specific T cells are the object of many studies and should be considered an innovative treatment approach for PyVA N.

AB - Advances in immunosuppression have lowered the acute rejection rates in kidney transplant recipients but have impacted negatively on the viral infection rates. Polyomavirus-associated interstitial nephropathy (PyVA N) affects up to 10% of kidney transplant recipients and can progress to irreversible allograft failure in up to 45% of affected cases. Nowadays, thanks to increased awareness of PyVA N and improved diagnostic techniques, the rate of graft loss has decreased, most markedly in centers with active screening and intervention programs. The diagnosis of PyVA N is made by allograft histology. However, systematic screening by quantitative molecular-genetic techniques allows intervention in the early stages of the disease, before the occurrence of irreversible parenchymal changes. So far, the only proven measure affecting PyVA N progression and outcome is the reduction of immunosuppression. Other therapeutic approaches including cidofovir, leflunomide, fluoroquinolones and intravenous immunoglobulins have been explored, but there is no clinical evidence supporting their efficacy. It has been largely demonstrated that BKV-specific T-cell immunity plays a pivotal role in controlling viral replication and disease progression. For this reason viral-specific T-cell immunity can help in monitoring PyVA N. Protocols of adoptive T-cell transfer based on infusion of BKV-specific T cells are the object of many studies and should be considered an innovative treatment approach for PyVA N.

UR - http://www.scopus.com/inward/record.url?scp=84940118237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940118237&partnerID=8YFLogxK

M3 - Articolo

C2 - 23059947

AN - SCOPUS:84940118237

VL - 29

SP - S99-S108

JO - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia

JF - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia

SN - 0393-5590

ER -